A multicenter, double-blind, parallel group, placebo controlled study of creatine in subjects with treated Parkinson’s disease (NETPD LS-1)
The major goal of this clinical trial is to institute a multicenter study to evaluate the efficacy of neuroprotective agents in Parkinson’s disease. The study is in the third phase of the NETPD project, called LS-1. The aim of this phase is to determine if creatine slows the progression of the disease defined by a combination of cognitive, physical, and quality of life measures. Active treatment with creatine will be compared to placebo control.
The study began in 2007 and is currently in the follow-up phase of the trial. The project is funded by the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH).
The NETPD group selected creatine based on their previous results from the NETPD FS-1 study sponsored by the NIH. This study investigated the safety and effectiveness of minocycline (an antibiotic) and creatine (a food supplement) as neuroprotective agents in people with early, untreated Parkinson’s disease and determined that creatine performed better than the futile threshold. The current study LS-1 intends to determine if there is any long term benefit.